An extension of studies to evaluate Abbv-951 in subjects with advanced Parkinson's disease (H-52937)

Abbvie Inc. - An Open-label extension of studies M15-736 and M20-339 to evaluate the safety and tolerability of 24-hour daily exposure of Abbv-951 in subjects with advanced Parkinson's disease

The purpose of this research is to look at how subcutaneous (under the skin) infusions of ABBV951 are absorbed in the blood stream and how the body handles them on patients with Parkinson’s disease.  ABBV-951 is an experimental drug, which means that the FDA has not approved it for the treatment of Parkinson’s disease or any other indication.